New reporting requirements for 2004 stuart herna ctr february 25 2004
Download
1 / 28

New Reporting Requirements for 2004 Stuart Herna, CTR February 25, 2004 - PowerPoint PPT Presentation


  • 60 Views
  • Uploaded on

New Reporting Requirements for 2004 Stuart Herna, CTR February 25, 2004. Part I: Collaborative Staging. What is Collaborative Staging? .

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' New Reporting Requirements for 2004 Stuart Herna, CTR February 25, 2004' - amos-pena


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
New reporting requirements for 2004 stuart herna ctr february 25 2004

New Reporting Requirements for 2004Stuart Herna, CTRFebruary 25, 2004



What is collaborative staging
What is Collaborative Staging?

  • Collaborative Staging is a group of data items designed to provide a single uniform set of codes and rules for collecting extent of disease and stage information.


Why a new coding system
Why A New Coding System?

  • To collect a unified data set in all registries to report to central agencies

  • CS uses best available clinical and pathologic data (may be mixed) for staging


When will cs go into effect
When Will CS Go Into Effect?

  • Implementation Date:

    • Cases diagnosed on or after January 1, 2004

    • NAACCR record layout Version 10.1


Collaborative staging data items
Collaborative Staging Data Items

  • 15 items in data set

    • 2 existing data items in FCDS data set

      • Regional Lymph Nodes Positive

      • Regional Lymph Nodes Examined

    • 13 new data items


Collaborative staging data items1
Collaborative Staging Data Items

  • CS Tumor Size

  • CS Extension

  • CS Tumor Size/Ext Eval

  • CS Lymph Nodes

  • CS Reg Nodes Eval

  • Regional LN Examined

  • Regional LN Positive


Collaborative staging data items2
Collaborative Staging Data Items

  • CS Mets At Dx

  • CS Mets Eval

  • CS Site-Specific Factor 1

  • CS Site-Specific Factor 2

  • CS Site-Specific Factor 3

  • CS Site-Specific Factor 4

  • CS Site-Specific Factor 5

  • CS Site-Specific Factor 6


Cs derived data items
CS Derived Data Items

  • CS has 12 derived data items

  • Derived data items are determined every time the computer algorithm is run

  • Derived fields are viewable only and cannot be changed or edited by the end user

  • If any CS data item(s) are revised, the CS algorithm must be recalculated to update the Derived CS data items


Cs derived data items1
CS Derived Data Items

  • Derived AJCC T

  • Derived AJCC N

  • Derived AJCC M

  • Derived AJCC T Descriptor

  • Derived AJCC N Descriptor

  • Derived AJCC M Descriptor


Cs derived data items2
CS Derived Data Items

  • Derived AJCC Stage Group

  • Derived AJCC Flag

  • Derived SS1977

  • Derived SS1977 Flag

  • Derived SS2000

  • Derived SS2000 Flag


Benefits of collaborative staging
Benefits of Collaborative Staging

  • Improved efficiency and quality of data

    • Unified rules

    • Standardized data set

    • Standardized training

    • Stage is derived from objective (factual) data

    • Accommodates future revisions


Benefits of collaborative staging1
Benefits of Collaborative Staging

  • Addition of TNM stage to FCDS data set

    • Enhances capability for research

    • Establishes a uniform data collection standard

  • Maintains independent objectives of users

    • Provides Longitudinal stability for epidemiologic and cancer control studies

    • Allows for data consistency over time


Impact on registrar
Impact On Registrar

  • More detailed information to collect but less interpretation

  • Registrars will not need separate reference manuals in order to assign a stage

  • Learning curve for new data elements


Cs additional information
CS Additional Information

  • www.training.seer.cancer.gov

  • http://www.cancerstaging.org/collab.html



Public law 107 260
Public Law 107-260

  • The Benign Brain Tumor Cancer Registries Amendment Act

    • Public Law 107-260

  • Signed by the President October 2002


Reportable brain related tumors
Reportable Brain-Related Tumors

  • Public Law 107-260 requires reporting of brain-related tumors

    • The term ‘brain-related tumor’ means a primary tumor (whether malignant or benign) occurring in any of the following sites:

      (I) The brain, meninges, spinal cord, cauda equina, a cranial nerve or nerves, or any other part of the central nervous system

      (II) The pituitary gland, pineal gland, or craniopharyngeal duct


Icd o 3 site codes
ICD-O-3 Site Codes

  • C70.0 - C70.9 Meninges

  • C71.0 - C71.9 Brain

  • C72.0 - C72.9 Spinal Cord, Cranial Nerves, other CNS

  • C75.1 Pituitary Gland

  • C75.2 Craniopharyngeal Duct

  • C75.3 Pineal Gland



Reporting requirements
Reporting Requirements Intracranial and CNS Tumors

  • Laterality to be coded for malignant and non- malignant CNS Tumors

    • C70.0, C71.0, C71.1, C71.2, C71.3, C71.4, C72.2, C72.3, C72.4, and C72.5

  • Sequence Numbers (non-malignant)

    • Are to be sequenced in the range of 60-87


Reporting requirements1
Reporting Requirements Intracranial and CNS Tumors

  • New rules have been created for determining multiple primaries (non-malignant only) based upon:

    Histology

    Sub site

    Laterality


Same histologic groupings for benign borderline brain tumors
Same Histologic Groupings for Benign/Borderline Brain Tumors Intracranial and CNS Tumors

  • Choroid plexus neoplasms

    9390/0, 9390/1

  • Ependymomas

    9383, 9394, 9444

  • Neuronal and neuronal-glial neoplasms

    9384, 9412, 9413, 9442, 9505/1, 9506

  • Neurofibromas

    9540/0, 9540/1, 9541, 9550, 9560/0

  • Neurinomatosis

    9560/1

  • Neurothekeoma

    9562

  • Neuroma

    9570

  • Perineurioma, NOS

    9571/0


Grade for non malignant brain and cns tumors
Grade for Non-Malignant Brain and CNS Tumors Intracranial and CNS Tumors

  • The 6th digit of the ICD-O 3 Histology Code describes tumor grade or differentiation

    - For non-malignant CNS tumors the 6th digit Grade Code is always 9 (not applicable)

    - The 6th digit ICD-O 3 Grade Code is not the same as the WHO Grade Code


Impact of new reporting requirements

New Edits Intracranial and CNS Tumors

Software modifications

Revision of the Data AcquisitionManual

Increased Workload

Training/Education

Teleconferences

Regional Workshops

Publications

Impact of New Reporting Requirements


Collaborative staging manuals
Collaborative Staging Manuals Intracranial and CNS Tumors

  • CoC will distribute one set of the Collaborative Staging Manuals to each CoC approved cancer program

  • FCDS will provide one set of the manuals to all non-approved facilities

    • Including Ambulatory Patient Care Centers


Fcds requirements
FCDS Requirements Intracranial and CNS Tumors

  • As of July 1st, 2004, all cases must be submitted in the NAACCR v10.1 record layout.

  • FCDS will not accept any 2004 cases prior to July 1, 2004.

  • 2003 cases not reported by the FCDS deadline of June 30, 2004 must be submitted to FCDS in the new NAACCR v10.1 record layout.


ad